394 related articles for article (PubMed ID: 31215680)
21. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
Dharmani P; Chadee K
Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
[TBL] [Abstract][Full Text] [Related]
22. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
23. Rheostat regulation of integrin-mediated leukocyte adhesion.
Douglas IS; Dassopoulos T
J Clin Invest; 2007 Sep; 117(9):2391-5. PubMed ID: 17786236
[TBL] [Abstract][Full Text] [Related]
24. Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD.
Liu H; Dasgupta S; Fu Y; Bailey B; Roy C; Lightcap E; Faustin B
BMC Immunol; 2019 Nov; 20(1):42. PubMed ID: 31718550
[TBL] [Abstract][Full Text] [Related]
25. Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?
Khanna R; Mosli MH; Feagan BG
Dig Dis; 2016; 34(1-2):153-9. PubMed ID: 26982012
[TBL] [Abstract][Full Text] [Related]
26. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
[TBL] [Abstract][Full Text] [Related]
27. Targeting Immune Cell Trafficking - Insights From Research Models and Implications for Future IBD Therapy.
Wiendl M; Becker E; Müller TM; Voskens CJ; Neurath MF; Zundler S
Front Immunol; 2021; 12():656452. PubMed ID: 34017333
[TBL] [Abstract][Full Text] [Related]
28. Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD.
Duijvestein M; D'Haens GR
Expert Opin Biol Ther; 2019 Apr; 19(4):361-366. PubMed ID: 30696342
[TBL] [Abstract][Full Text] [Related]
29. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
[TBL] [Abstract][Full Text] [Related]
30. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
Wyatt NJ; Speight RA; Stewart CJ; Kirby JA; Lamb CA
BioDrugs; 2021 Sep; 35(5):473-503. PubMed ID: 34613592
[TBL] [Abstract][Full Text] [Related]
31. Vedolizumab for the treatment of inflammatory bowel disease.
Haddley K
Drugs Today (Barc); 2014 Apr; 50(4):309-19. PubMed ID: 24918648
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
Catalan-Serra I; Brenna Ø
Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
[TBL] [Abstract][Full Text] [Related]
33. Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.
Zundler S; Neurath MF
Inflamm Bowel Dis; 2017 Apr; 23(4):617-627. PubMed ID: 28296823
[TBL] [Abstract][Full Text] [Related]
34. An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease.
Brubaker DK; Kumar MP; Chiswick EL; Gregg C; Starchenko A; Vega PN; Southard-Smith AN; Simmons AJ; Scoville EA; Coburn LA; Wilson KT; Lau KS; Lauffenburger DA
Sci Signal; 2020 Aug; 13(643):. PubMed ID: 32753478
[TBL] [Abstract][Full Text] [Related]
35. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease.
Bamias G; Clark DJ; Rivera-Nieves J
Curr Drug Targets; 2013 Nov; 14(12):1490-500. PubMed ID: 23621509
[TBL] [Abstract][Full Text] [Related]
36. A mutation that blocks integrin α
Zhang H; Zheng Y; Pan Y; Lin C; Wang S; Yan Z; Lu L; Ge G; Li J; Zeng YA; Chen J
BMC Biol; 2020 Jun; 18(1):64. PubMed ID: 32522281
[TBL] [Abstract][Full Text] [Related]
37. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go.
Stefanelli T; Malesci A; De La Rue SA; Danese S
Autoimmun Rev; 2008 May; 7(5):364-9. PubMed ID: 18486923
[TBL] [Abstract][Full Text] [Related]
38. Review article: anti-adhesion therapies for inflammatory bowel disease.
Lobatón T; Vermeire S; Van Assche G; Rutgeerts P
Aliment Pharmacol Ther; 2014 Mar; 39(6):579-94. PubMed ID: 24479980
[TBL] [Abstract][Full Text] [Related]
39. Distinct patterns of naive, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn's disease.
Rabe H; Malmquist M; Barkman C; Östman S; Gjertsson I; Saalman R; Wold AE
Clin Exp Immunol; 2019 Jul; 197(1):111-129. PubMed ID: 30883691
[TBL] [Abstract][Full Text] [Related]
40. Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects.
Zundler S; Becker E; Weidinger C; Siegmund B
Front Immunol; 2017; 8():891. PubMed ID: 28804488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
